Page 1

Exhibit 99.1 Highlights : • • • • Agilent Reports Third - Quarter Fiscal Year 2021 Financial Results Delivers Very Strong Results , Raising Full - Year Guidance Revenue of $ 1.59 billion represents an increase of 26 % reported growth year - over - year , up 21 % on a core ( ¹ ) basis . GAAP diluted earnings per share ( EPS ) of 86 cents , up 34 % . Non - GAAP ( 2 ) diluted EPS of $ 1.10 per share , up 41 % . Full - year guidance raised with revenue now expected to be in the range of $ 6.29 billion to $ 6.32 billion and non - GAAP ( 3 ) EPS of $ 4.28 to $ 4.31 . Fourth - quarter revenue expected to be in the range of $ 1.63 billion to $ 1.66 billion with non - GAAP ( 3 ) EPS of $ 1.15 to $ 1.18 . SANTA CLARA , Calif . , Aug. 17 , 2021 - Agilent Technologies Inc. ( NYSE : A ) today reported revenue of $ 1.59 billion for the third quarter ended July 31 , 2021 , an increase of 26 % compared to the third quarter of 2020 and up 21 % on a core ( ¹ ) basis . Third - quarter GAAP net income was $ 264 million , or 86 cents per share . This compares with $ 199 million , or 64 cents per share , in the third quarter of fiscal year 2020. Non - GAAP ( 2 ) net income was $ 337 million , or $ 1.10 per share compared with $ 243 million , or 78 cents per share , during the third quarter a year ago . " The positive momentum in Agilent's business continued in the third quarter across all markets and regions as our performance exceeded our expectations , " said Mike McMullen , Agilent president and CEO . " Our focus on high- growth businesses and strong execution has again led to another quarter of excellent results and we expect this momentum to continue as we close out our fiscal year . " Financial Highlights Life Sciences and Applied Markets Group Third - quarter revenue of $ 680 million from Agilent's Life Sciences and Applied Markets Group ( LSAG ) was up 22 % year - over - year and 18 % on a core ( ¹ ) basis . LSAG's operating margin was 25.0 % . Agilent CrossLab Group Third - quarter revenue of $ 560 million from the Agilent CrossLab Group ( ACG ) increased 21 % year - over - year and was up 15 % on a core ( ¹ ) basis . ACG's operating margin was 29.3 % . Diagnostics and Genomics Group 1